Results 231 to 240 of about 1,750,371 (298)

Evaluating EndoC βH5 pseudoislets as a model for human islet transplantation

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims The EndoC βH5 cell line represents a promising human β‐cell model for preclinical diabetes research. Indeed, EndoC βH5 cells aggregate into islet‐like organoids, secrete insulin in a glucose‐dependent manner, and express a variety of β‐cell functional markers.
Lydia F. Daniels Gatward   +11 more
wiley   +1 more source

PPI and researcher perspectives of islet transplantation therapy for type 1 diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Islet transplantation offers the potential of a cure for type 1 diabetes (T1D), but the limited availability of human donor islets means that this therapy is currently only available to a small group of people with T1D who have intractable hypoglycaemia.
Peter M. Jones   +15 more
wiley   +1 more source

Comparing the Validity of Three Methods for Identifying Impaired Awareness of Hypoglycemia in Predicting Severe Hypoglycemia in Adults with Type 1 Diabetes Mellitus: The PR-IAH Study. [PDF]

open access: yesIntern Med
Sakane N   +12 more
europepmc   +1 more source

DiaActive protocol: A randomized controlled trial of cognitive‐motor multicomponent exercise to reduce fall rate in older adults with diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction Older adults with diabetes have an increased risk of falls due to neuropathy, impaired bone health and cardiovascular disease, resulting in significant morbidity and mortality. Conventional fall‐prevention programmes primarily target strength and balance, while cognitive‐motor integration, essential for safe mobility in complex ...
Aksayan Arunanthy Mahalingasivam   +4 more
wiley   +1 more source

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy